Biomarkers · Inflammation

Antinuclear Antibodies (ANA)

The published study could not tell whether risk rises or falls: its 95% interval includes no change. No risk curve catalogued yet.

Published risk of death1.13×ANA positive (1:80 dilution) vs ANA negative (95% CI 0.79–1.60) · NHANES 1999-2004 adults aged >=20 years with ANA measurements, mortality through 2011, USA

What else moves this marker

They describe those study groups, not an individual, and an association is not a cause.

Diseases and conditions

Each row is one study: what it compared and the change it reported in this marker.
What	Effect on the marker	Comparison · population	Source
↑ Acute cytomegalovirus infection · ANA seropositivity, acute CMV vs acute EBV infection	+50%	acute CMV (79% ANA positive) vs acute EBV (29% ANA positive) · 52 immunocompetent hospitalised adults with serologically confirmed acute EBV or CMV, Israel	cross sectional · PMID 41381367

Sources

Dinse et al. Antinuclear antibodies and mortality in the National Health and Nutrition Examination Survey (1999-2004). PloS one. 2017;12:e0185977.